"Pharmaceutical Express" Novart Inclisiran Phase 3 Clinical Active Xinlitai transfer 5% of the equity

September 3, 2020 / Medical Information List: Tianslike's application for listing was accepted by the Shanghai Stock Exchange; Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief Health Insurance Bureau announced: The total cost control fee began recently, Qinghai Health Insurance Bureau issued the "Interim Measures for the Administration of Total Medical Insurance Payments in Qinghai Province" notice, and asked the provincial, municipal (state) health insurance agencies in accordance with the provisions of the Measures, as soon as possible to approve the total amount of the 2020 health insurance fund payments.
shall be implemented 30 days after the date of issuance and shall be valid for two years.
(Qinghai Provincial Health Insurance Bureau) Part 2 After observing the listing application of Tianslike Board was accepted by the Shanghai Stock Exchange Tiansli issued a notice that the company received on September 3, 2020 the SSE issued "on the acceptance of Tiansli Biopharmaceutical Co., Ltd. initial public offering of shares and listing applications on the Science and Technology Board notice."
SE.S. Stock Exchange in accordance with the relevant provisions of the initial public offering of shares submitted by Tiansli Bio and listed on the Board of Science and Technology application report and related application documents have been checked, the application documents are complete, in accordance with the legal form, decided to accept and be reviewed in accordance with the law.
(Tiansli Announcement) Xinlitai transfer 5% of the shares 1, Xinlitai announced that through the transfer of the agreement, the total holding of the company's 52,300,800 shares of unlimited sale of shares (5% of the company's total share capital) transferred to CITIC Lyon Asset Management Co., Ltd., the transfer price of 33.94 yuan / share, the total transfer price of more than 1775 million yuan.
(Pharmaceutical Rubik's Cube) Lyell and Orca have teamed up to develop solid tumor cell therapy Orca and Lyell announced today that they have reached a research collaboration that combines Orca's precision purified T-cell technology with Lyell's scientific expertise in T-cell biology to develop a new generation of T-cell therapies for solid tumors.
a $11.5 million deal between unum and Czech Bio, Unum announced the sale of its BOXR platform and its main candidate, CAR-T product BOXR1030, to Czech biotech company SOTOIO.
agreement, the deal is worth $11.5 million, including an $8.1 million advance payment from SOTO to Unum and a potentially high milestone payment of $3.4 million in the future.
(Shell Society) Fangrun Medical completed hundreds of millions of yuan B round of financing Fangrun Medical announced the completion of hundreds of millions of yuan B round of financing, led by the fund of CHINA Capital, Qianyu Capital, Apricot Capital, Daoyu Investment and Huaxing Capital, mainly used in the company's product development, marketing and commercial preparation.
(Sina Pharmaceutical News) Huayuan Bio received tens of millions of yuan A round of financing Hua yu Bio recently announced the completion of tens of millions of yuan of A round of equity financing.
this round of financing is jointly invested by Beijing First Development Tianyu Fund, Detong Capital and an international industrial group, and Hao Yue Capital serves as the exclusive financial advisor in this transaction.
(E.U. Health Official) Part 3 Drug News Novardo Tabrecta Treatment of METex14 Mutations NSCLC Patient Key Results released 2, NEJM published the positive results of Novartic Tabrecta's Key Phase 2 clinical study GEOMETRY mono-1.
data showed that Tabrecta's overall response rate for metastasis non-small cell lung cancer (NSCLC) adult patients treating the MET exon 14 jump (METex14) mutation was positive and the duration of remission was positive.
(Sina Pharmaceutical News) Novartis semi-annual injection of atherosclerosis fat-lowering key Phase 3 clinical trial results positive Novartis recently announced the evaluation of its first cholesterol-lowering drug Inclisiran treatment of adult hyperlipidemia two key Phase 3 clinical trial summary data after-the-fact analysis results.
both trials evaluated Inclisiran's effectiveness in lowering LDL cholesterol in patients.
analysis showed that in patients at risk, such as atherosclerosis (ASCVD) or ASCVD, who had been follow-up for more than 17 months, Inclisiran performed semi-annual subsurfic injection maintenance therapy after the initial dose (3 months after the first dose), showing a high degree of consistent reduction in LDL-C efficacy in different patients, with similar safety and tolerance to placebos.
(Immediate Drug News) Lilly RET targeted drug Selpercatinib Start Phase III Clinical 1, Lilly's new drug Selpercatinib Start Phase III Clinical, used to treat RET mutant thyroid myelin-like cancer.
this clinical trial is the second phase III clinical trial of the drug initiated in China.
clinical trial for advanced or metastasis RET fusion-positive non-small cell lung cancer is currently under way.
Database Novavax New Crown Candidate Vaccine Clinical Phase 1 Shows Good Safety and Reactive Originality 2, a study published in the New England Journal of Medicine, "Novavax's COVID-19 Candidate Vaccine NVX-CoV2373" Phase 1 clinical data from Phase 1 clinical trials showed that the vaccine candidate was used in healthy adults aged 18-59 years, showed reassuring safety and reactive primary characteristics, and induced neutral antibody titration up to four times that of patients with recovery COVID-19.
(Now) Roche COVID-19 antigen testing products listed in Europe Roche recently announced that it will be in the market at the end of September to accept the CE mark to launch a new coronavirus rapid antigen detection product SARS-CoV-2 Rapid Antigen Test.
, the company intends to apply to the FDA for emergency authorization.
(Sina Pharmaceutical News) China biopharmaceutical ROCK2 inhibitor declaration clinical has been carried out in the United States clinical 2, China Biopharmaceutical announced that the group's independent research and development of innovative therapeutic fibrosis drug TDI01 has submitted to CDE clinical trial applications, and was accepted.
, TDI01 has been approved for FDA clinical trials in the United States, the product is currently in the United States to start phase 1 clinical administration trials.
currently, the product is clinically adapted to non-alcoholic fatty hepatitis and pulmonary fibrosis.
(Pharmaceutical Mission) Hengrui PD-1 new adaptive drug listing application to be included in the priority review: first-line nasopharyngeal cancer 2, CDE publicity, Hengrui Pharmaceutical Innovation PD-1 antibody Karelli pearl monoanti (Erika) to be included in the priority review, on the grounds that: eligible drugs approved.
According to Henrui Pharmaceuticals previously announced, this Carelli pearl monoantigen in CDE submitted a new adaptive disease listing application, intended for use in the joint cisplatin and Gissythabhamin first-line treatment of local recurrence or distant metastatic nasopharyngeal cancer patients.
(CDE) Xinda BioAdam single anti-injection was approved by NMPA Xinda Bio-Adamo single-anti-injection by NMPA approved for listing, becoming the third domestic Adamo single anti-biological similar drugs.
Adamo monoantigen injection is an anti-TNF-α monoclonal antibody, and the approved adaptation of the Cynda bioAdam monoantigen injection is expected to be strong straight spina blinitis.
(NMPA) AstraZeneta Grealo Dispersion Tablets were approved in China according to the NMPA Drug Approval Notice, AstraZeneta Grealo Dispersion Tablets china was approved for listing.
Terriello is a small molecule ADP inhibitor approved for the drug's new dosage form, the dispersion tablet is designed to provide a new option for patients with difficulty swallowing or who can only be treated by intestion.
(NMPA) Sanofi's insulin glycelin injections have been approved for listing in China, according to a notice issued under the NMPA drug approval.
insulin injection is a unique slow-release mechanism developed by Sanofi for type 2 diabetes in adults who require insulin treatment.
insulin release is slower and more stable after injection, making blood sugar control smoother and more effective.
(NMPA) Love Pharmaceuticals' Ado sulfate enzyme β injection was approved by NMPA for listing according to the NMPA drug approval notice, No love pharmaceutical company's Ado sulfate enzyme β injection was approved for listing by NMPA.
Adosinase β injection is a recombinant adrenaline replacement therapy for Hunter syndrome.
(NMPA) Baillie Pharmaceuticals in the study of anti-cancer drugs approved clinical CDE latest publicity, Baili Pharmaceuticals 1 class of new drug GNC-038 four-specific antibody injection obtained a clinical implied license, the adaptive disorder is "intended for relapsed or refractic non-Hodgkin lymphoma, recurring or refractic acute lymphoblastic leukemia, refractic or metastatic solid tumor treatment."
(CDE) North Sea Kangcheng introduced the β Edo sulfate enzyme β injection" will be approved in China, Beihai Kangcheng submitted for the treatment of Hunter's syndrome, Ado sulfate enzyme β injection new drug market application into the "approval" stage, is expected to be approved in China in the near future.
has been included in China's "First Rare Diseases List", but at present, China has not approved the treatment of Hunter syndrome treatment program.
(Pharmaceutical Rubik's Cube) WHO large-scale meta-study confirmed that corticosteroids can reduce mortality in severe neo-crown patients WHO's COVID-19 Rapid Evidence Assessment Team published large meta-analysis results in JAMA, which found that severe COVID-19 patients treated with corticosteroids had a 34 percent lower risk of total cause of death after 28 days in a randomized group than in the control group.
results further confirm the results of a large clinical trial in THECOVERY, the UK, which significantly reduced the 28-day mortality rate in patients.
(Pharmaceutical Minder)